Últimos Artículos de Lancet Diabetes & Endocrinology
- [Personal View] Time to reframe the disease staging system for type 1 diabetes
- [Correspondence] Medications for obesity as preventatives: a public and patient safety issue
- [Editorial] Putting wellbeing at the core of diabetes care
- [Articles] Trends in the incidence of young-adult-onset diabetes by diabetes type: a multi-national population-based study from an international diabetes consortium
- [Comment] Global diabetes incidence trends in young adults
- [Comment] Disease modifying therapies in diabetes and endocrinology
- [Comment] Staging schema for early diagnosis of prediabetes
- [Articles] Depression symptoms, wellbeing, health-related quality of life, and diabetes-related distress in novel subtypes of recent-onset diabetes in Germany: a 5-year observational follow-up study
- [Comment] Diabetes subtypes and patient-reported outcomes
- [Articles] Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92)
- [Comment] Young adult-onset type 2 diabetes heralds a poor prognosis
- [Articles] Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study
- [Comment] Lomitapide for the treatment of homozygous familial hypercholesterolaemia in children
- [Correspondence] Declaration of Lisbon
- [Viewpoint] Continuous glucose sensor accuracy: beyond the headline metric
- [Comment] Lessons to learn from the 2024 NICE guideline on adrenal insufficiency
- [Editorial] Stem-cell therapy for diabetes: the hope continues
- [Articles] Evolving epidemiological patterns of thyroid cancer and estimates of overdiagnosis in 2013–17 in 63 countries worldwide: a population-based study
- [Comment] The growing global burden of thyroid cancer overdiagnosis
- [Articles] Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1